Skip to main content
Premium Trial:

Request an Annual Quote

Genetix, Sense Proteomic to Collaborate on Protein Arrays

NEW YORK, Oct. 31 - Genetix Group of New Milton, UK, said Wednesday it had agreed to collaborate with Sense Proteomic to develop a new line of protein arrays.

Genetix said it agreed to work with Sense Proteomic’s of Cambridge, UK, to deploy Sense’s COVET technology in four prototype products. The companies expect to launch the new arrays commercially next year. 

According to Genetix, the COVET technology can express, purify, and array thousands of proteins in a spatially defined format. The proteins arrayed are correctly folded and fully functional, allowing users to more easily identify new drug targets and potential candidates.

“The Genetix Group, like others in the industry, view protein arrays as an area of growth,” Mark Reid, CEO of Genetix, said in a statement. “Sense Proteomic has a unique technology and product portfolio and it is an exciting challenge to help bring these products to market.”

The companies did not disclose the financial terms of the deal.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.